BioArctic (BIOA) DNB Nordic Healthcare Conference Presentation summary

Strategic focus and leadership in neurodegenerative diseases

• Specializes in disorders with large unmet needs, including Alzheimer's, Parkinson's, and ALS.

• Recognized for world-class R&D and strong collaborations, notably with Eisai.

• Leqembi is the first fully approved disease-modifying therapy for Alzheimer's, establishing a new standard of care.

• Broad project portfolio leveraging two technology platforms: selective antibodies and Brain Transporter.

• Financially robust, supported by milestone payments and 9% royalties on global Leqembi sales.

Leqembi global commercialization and regulatory progress

• Fully approved in the US, Japan, China, South Korea, Great Britain, and more; pending EU approval by February 2025.

• EMA's CHMP issued a positive opinion for a restricted patient population after re-examination.

• US sales lag expectations due to infusion bottlenecks, but Japan and China show strong growth.

• Eisai revised FY 2024 Leqembi sales forecast downward, but mid- and long-term outlooks remain unchanged.

• Ongoing development includes subcutaneous and autoinjector formulations to improve convenience.

Clinical data and patient impact

• Early treatment with Leqembi results in over 50% slowing of decline in patients with low amyloid.

• More than half of patients with no or low tau improved over three years.

• Simplified diagnosis using blood-based biomarkers and digital platforms could expand patient access.

• Potential for broadened indications, including pre-symptomatic Alzheimer's.